Materials and Methods: 167 patients were randomized between WBI with a SeqB or a SIB. 150 patients were treated at Ghent University Hospital (UZ Gent) and 17 at Liège University Hospital. All patients were treated in prone position to 40.05 Gy in 15 fractions to the whole breast. In the SeqB arm a median dose of 10 Gy in 4 fractions (negative surgical margins) or 14.88 Gy in 6 fractions (transsection) was prescribed to the PTV_boost (CTV to PTV margin of 5 mm). In the SIB arm a median dose of 46.8 or 49.95 Gy (negative and positive surgical margins, respectively) was prescribed to the CTV_boost with dose decay to 40.05 Gy in the first 2 cm around the CTV_boost. In the SeqB arm dose parameters were calculated on the summed plan (WBI + boost). For comparison, a PTV_optim was created including the PTV for WBI more than 2 cm away from the CTV_boost as illustrated in Figure 1 .
Dermatitis was scored using the Common Toxicity Criteria for Adverse Events (CTCAE). Desquamation was scored as: none, dry or moist; pruritus as absent or present.
Results: The analysis of dose parameters was done on 146 patients treated at UZ Gent. Reasons for excluding patients were electron boost (2), 3 different plans on 3 different CTs (1) and changed treatment arm due to machine breakdown (1). This latter patient was excluded from the toxicity analysis as well. Patient age was the only significantly different parameter between treatment arms (mean age 59.6 ± 11.0 vs 55.7 ± 10.4 years, p=0.0210). Dose coverage of the CTV_boost was slightly better in the control arm (D95 of 98 ± 1% vs 97 ± 2%, p<0.01). The volume of the PTV_optim and the skin receiving more than 105% of the prescription dose were significantly higher in the SeqB-arm than in the SIB-arm (27 ± 20% vs 9 ± 6% for the PTV_optim and 394 ± 216cc vs 201 ± 125cc for the skin, both p<0.01).In both arms, 6/83 patients developed moist desquamation (primary endpoint). Grade 2/3 dermatitis was significantly more frequent in the SeqB arm (38/83 vs 24/83 patients, p=0.037). In the SIB and SeqB arm, respectively, 36 and 51 patients developed pruritus (p=0.015). The incidence of edema was lower in the SIB arm (59 vs 68 patients), but not statistically significant (p=0.071).
Conclusion: Acute toxicity is not increased using a SIB in prone hypofractionated WBI. In contrast, grade 2/3 dermatitis and pruritus are significantly less frequent. With our SIB-technique, high dose regions outside the boost region are smaller than with a SeqB.
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Materials and Methods:
From 2009-2014 1868 patients >40 years operated with breast conservation for early pT1-2 pN0-1(mic) BC (n=1617) or DCIS (n=251) were enrolled irrespective of breast size, systemic therapy and boost, and randomized 50 Gy/25 fr vs. 40Gy/15 fr. Strata were institution, breast size (≤ 600 ml vs. > 600 ml), systemic therapy and boost. The primary endpoint was grade 2-3 induration 3 years post RT, secondary endpoints were other normal tissue responses, genetic risk profile for RT-induced fibrosis and recurrences. ClinicalTrial NCT00909818.
Results: 942 pts (50.4%) were assigned to the 50 Gy group and 926 (49.6%) to the 40 Gy group. Median age was 59 years (range 39-83). Median follow up was 3 years. The analysis was by intention to treat. Results are actuarial 3 year rates using morbidity in 1801 pts 1 yr post RT as baseline. 1086 pts (60%) had 3 year scores of morbidity and the rate of grade 2-3 induration was 12.2%±1%. Grade 2-3 induration was seen in the 50 Gy group in 119 out of 904 pts with the rate 14.2%±1.4%, and in the 40 Gy group in 97 out of 897 pts, the rate being 10.1% ±1%, representing a HR 1.27 (95% CI 0.97-1.66), p=0.08. 859 pts (48%) had small breasts with a rate of grade 2-3 induration of 9.8%±1% compared to 14.3%±1% among 942 pts with large breasts, HR 1.56, (95% CI 1.18-2.05), p=0.001. Among the 653 pts (36%) treated with chemotherapy (CT) the rate of grade 2-3 induration was 12.4%±1%, whilst in the 1148 pts with no CT the rate was 11.8%±2%, HR 0.98 (95% CI 0.74-1.30), p=0.90. In 423 pts (23%) treated with sequential boost (10-16 Gy/5-8 fr) the rate of grade 2-3 induration was 12.4%±1% compared to 12.1%±1% among 1378 pts with no boost, HR 0.93 (95% CI 0.67-1.29), p=0.65. Multivariate analysis using grade 2-3 induration at 3 yr as endpoint and including hypofractionation, breast size, chemotherapy and boost identified large breast size as the only independent risk factor. Overall the 3 yr risk of loco-regional recurrence was 0.3%±0.1%. In the 50Gy / 40 Gy group loco-regional recurrence was reported in 2 pts / 4 pts, distant failure 4 pts / 3 pts, new contralateral cancer or DCIS 2 pts / 3 pts.
Conclusion:
Moderately hypofractionated whole breast irradiation in early node-negative BC or DCIS does not result in more grade 2-3 induration compared to normofractionated therapy. Large breast size is an independent risk factor for developing induration. The 3 yr loco-regional recurrence risk is very low.
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